12/28/2022
The case was a victory against prescription drug monopolies, which delay the availability of less expensive generic drugs and artificially inflate the cost of health care. We are delighted that the TJC will be able to use these funds to help indigent Tennessee citizens access healthcare and provide additional assistance to those in need throughout our state.
This award comes from the settlement of an antitrust class action against Mutual Pharmaceutical Company Inc. The suit was filed in 2012 on behalf of individuals and entities in 29 states who purchased the muscle relaxer Skelaxin and its generic equivalent metaxalone between 2005 and 2014. The U.S. District Court for the Eastern District of Tennessee approved a $9 million settlement with the company and selected TJC to receive the award from funds that were undistributed to class members! This award will help us to continue our heart work. Thank you Branstetter, Stranch & Jennings, PLLC!